SLDB Solid Biosciences Inc.
Price Chart
Executive Summary
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $56.7M from $39.3M a year ago. The company highlighted Phase 3 Duchenne trial initiation and a strong cash position of $380.7M extending into H1 2028, but the earnings miss and rising R&D costs overshadow pipeline progress.
Actionable Insight
The EPS miss and widening losses are negative, but the strong cash position and Phase 3 Duchenne trial progress provide a floor. Watch for FDA guidance on accelerated approval for SGT-003 and initial FALCON data by year-end 2026 as potential catalysts.
Key Facts
- Q1 2026 EPS of -$0.53 missed consensus of -$0.44 by 20.9%
- Net loss widened to $56.7M from $39.3M in Q1 2025
- Cash, cash equivalents and securities totaled $380.7M as of March 31, 2026, up from $187.9M at year-end 2025
- R&D expenses rose to $46.1M from $30.9M, driven by SGT-003 manufacturing and clinical costs
- First participant dosed in Phase 3 IMPACT DUCHENNE trial for SGT-003
- 47 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial as of May 11, 2026
- Two participants dosed in Phase 1b FALCON trial for Friedreich's ataxia; no serious adverse events
- Cash runway expected into H1 2028
Financial Impact
EPS miss of 20.9% vs consensus; net loss increased 44.4% YoY to $56.7M
Risk Factors
- Continued cash burn with no near-term revenue; R&D costs may rise further
- Regulatory setbacks or delays in SGT-003 accelerated approval pathway
- Competition from other Duchenne gene therapies (e.g., Pfizer, Sarepta)
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293411 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
4w ago
|
Press Release
| $7.38 $6.08 | ▲ +17.62% | ▲ +16.46% | $7.14 (+3.25%) |
|
May 7, 2026
5w ago
|
Press Release
| $7.07 $7.38 | ▲ +4.38% | ▲ +2.88% | $7.14 (+0.99%) |
|
Apr 23, 2026
7w ago
|
DEFA14A
| $7.92 $7.26 | ▼ −8.33% | ▼ −9.24% | $7.14 (−9.85%) |
|
Apr 10, 2026
9w ago
|
8-K
| $8.39 $8.49 | ▲ +1.19% | ▼ −2.10% | $7.14 (−14.90%) |
|
Apr 1, 2026
10w ago
|
EFFECT
| $7.38 $8.10 | ▼ −9.76% | ▼ −5.99% | $7.14 (+3.25%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $7.03 $7.11 | ▲ +1.14% | ▲ +3.29% | $7.14 (+1.56%) |
|
Mar 12, 2026
13w ago
|
8-K
| $7.71 $7.12 | ▼ −7.65% | ▼ −6.67% | $7.14 (−7.39%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $7.72 $7.12 | ▼ −7.71% | ▼ −5.52% | $7.14 (−7.45%) |
|
Mar 6, 2026
14w ago
|
Press Release
| $6.75 $7.31 | ▲ +8.30% | ▲ +9.82% | $7.14 (+5.78%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $5.96 $8.18 | ▲ +37.25% | ▲ +37.73% | $7.14 (+19.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access